TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03752788

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual-task Training Fixed Priority
Description: Dual-task training fixed priority instructional set for four weeks. Balance training sessions of 45 minutes per day, 3 times a week for four weeks, so as to complete 9-12 hours of training warm-up improve the balance performance. This included 12 repetitions in each session for 30 minutes after a 10-minutes warm up.~Attention was focused on both postural and cognitive tasks throughout this session. In postural tasks, subjects were instructed to perform the following: walk narrow base of support with a cognitive task of counting backward by three walk narrow base of support with cognitive task of count forward by three, walk narrow base of support, step, sideways, backward avoiding the obstacles (holding a basket) with cognitive task to remember words.
Study: NCT00323401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antenatal classes
Description: 3 sessions of 3 hours each
Study: NCT04622670

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Attend yoga class
Study: NCT02563002

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6
Description: Regimen consists of oxaliplatin 85 mg/m\^2 IV on Day 1, leucovorin 400 mg/m\^2 or levoleucovorin 200 mg/m\^2 IV on Day 1, 5-fluorouracil (5-FU) 400 mg/m\^2 IV bolus on Day 1 and then 1200 mg/m\^2/day IV over 2 days for total dose of 2400 mg/m\^2 in each 2-week cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: Regimen consists of irinotecan 180 mg/m\^2 IV on Day 1, leucovorin 400 mg/m\^2 or levoleucovorin 200 mg/m\^2 IV on Day 1, 5-FU 400 mg/m\^2 IV bolus on Day 1 and then 1200 mg/m\^2/day IV over 2 days for total dose of 2400 mg/m\^2 in each 2-week cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT03752788

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dual-task Training Variable Priority
Description: Dual-task training variable priority instructional set for four weeks. Balance training sessions of 45 minutes per day, 3 times a week for four weeks, so as to complete 9-12 hours of training warm-up improve the balance performance. This included 12 repetitions in each session for 30 minutes after a 10-minutes warm up.~During the first half of the training session, attention was focused on postural tasks, while during the remaining half of the session, attention was focused on cognitive tasks.
Study: NCT04158674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: Levosimendan 2.5mg/ml, solution to be diluted for infusion Dilution in a 500ml bag of 5% Glucose The product is administered as a continuous infusion for 24 hours at an initial rate of 0.2 µg/kg/min

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Cernevit
Description: mixture of 12 vitamins The dilution of the treatment is done in a 500ml bag of 5% Glucose The product is administered as a continuous infusion for 24 hours at an initial rate of 0.2 µg/kg/min
Study: NCT02563002

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: IV infusion
Study: NCT02162771

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Study: NCT00924209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1250 mg/m\^2 dose for two doses on days 1 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80 mg/m\^2 on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5 mg/m\^2 on day 1 every 21 days for first two cycles only

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: thoracotomy with lobectomy/pneumonectomy and mediastinal lymph node dissection 4-6 weeks post completion of last cycle of cisplatin
Study: NCT02013388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N91115
Description: Given PO daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N91115
Description: Given PO daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N91115
Description: Given PO daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N91115
Description: Given PO daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N91115
Description: Given PO only on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N91115
Description: Given PO only on Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Day 1 only
Description: Given PO- only on Day 1 (single dosed to match single dose treatments)
Study: NCT00924209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m\^2 intravenous per day for consecutive 3 days on days 1 to 3 every 3 weeks for 4 cycles.
Study: NCT00735501

Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency as well as dose alterations to be determined by the physician according to normal clinical evaluation
Study: NCT04141449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Potlako intervention
Description: Combined provider, patient, and health system intervention to expedite cancer diagnosis and care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced care
Description: Provider education and limited patient counseling.
Study: NCT03900598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-67856633
Description: JNJ-67856633 capsule will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-67856633
Description: JNJ-67856633 capsule will be administered orally.
Study: NCT01674309

Intervention type: DRUG
Group type: OTHER
Intervention: FOLFORINOX
Description: INTRAVENOUS administration
Study: NCT03685396

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich fibrin ( PRF)
Description: Venous blood was collected with a butterfly needle in two 10 mL tubes without anticoagulants or other chemicals. The tubes were immediately centrifuged at 3000 rpm for 10 minutes.~At the end of centrifugation a fibrin clot (PRF) was obtained in the middle of the tube, just between the red corpuscles at the bottom and acellular plasma at the top. The PRF clot was taken from the tube and the red cells portion at the base of the clot was eliminated with sterile scissors Then the PRF was enveloped in sterile gauzes and positioned between two glass plates: the compression drove out the serum from the clot obtaining PRF membranes that were ready to be used in the surgical site.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hemostatic agents with oxidized and regenerated cellulosa
Description: In the Control Group hemostatic agents with oxidized and regenerated cellulosa were sutured to the palatal wound with mattress suture ( silk 5/0).
Study: NCT02768610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study: NCT01889173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102 SL Tablets at 2.8 mg
Description: 1 x TNX-102 SL Tablet (with potassium phosphate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102-B SL Tablets at 2.8 mg
Description: 1 x TNX-102-B SL Tablet (with sodium phosphate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102-C SL Tablets at 2.8 mg
Description: 1 x TNX-102-C SL Tablet (with trisodium citrate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclobenzaprine tablets
Description: 1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
Study: NCT02401464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-536 Tablet
Description: TAK-536 10 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-536 Tablet
Description: TAK-536 10 mg tablet
Study: NCT03154684

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: STARK intervention
Description: The STARK Intervention is a new care concept for hip fracture patients that enable hip fracture patient to return to their home directly after discharge from acute care. The STARK comprehensive autonomy health care package includes following services;~* Multidisciplinary collaboration of geriatricians, nurses and Spitex (ambulant nursing service at home) starting already during acute care~* Inspection of the environment at the patient's home~* Care and autonomy support~* Social life support~* Secondary prevention strategies:~* Home exercise program (3x/weeks)~* Protein enriched food preparation (20g whey protein/day)~* Support to take vitamin D supplementation (2000 IU/day)~* Recommendation and support to eat calcium rich foods~* Motivation to be physically active

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of Care involves inpatient rehabilitation or home-based or inpatient transitional nursing care
Study: NCT03377959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Mat Classes
Description: The intervention, the exercises, and their progressions were systematized based on protocol proposed by Siler (2008).
Study: NCT02497781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftazidime -avibactam
Description: Patients randomised (3:1) to the CAZ-AVI or cefepime treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefepime
Description: Patients randomised (3:1) to the CAZ-AVI or cefepime treatment
Study: NCT00745095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine
Description: Neostigmine will be administered in 20, 40, and 60mg doses until an individualized dose-response relationship is established

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine
Description: Neostigmine will be administered in 20, 40, and 60mg doses until an individualized dose-response relationship is established
Study: NCT02529059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eviplera
Description: A single-pill fixed dose combination of tenofovir 245mg, emtricitabine 200mg and rilpivirine 25mg once daily for 24 weeks.
Study: NCT00858195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin 75mg Extended-Release Capsules, Sandoz

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indocin 75mg SR Capsules
Study: NCT03339037

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric oxygen therapy
Description: 60 HBOT sessions at 2 ATA 100% oxygen

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Normobaric air SHAM
Description: 60 sessions at 1 ATA 21% oxygen (air)
Study: NCT00581620

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pneumococcus conjugate vaccine
Description: Infants from 1 to 6 months: 3 doses at 2; 4; 6 m and booster from 12 to 15 months.
Study: NCT03377959

Intervention type: OTHER
Group type: OTHER
Intervention: Ballet Classes
Description: The intervention is ballet classes three times a week, 1 hour and 30 min. The ballet classes consists in barre work and center work with specific ballet exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ballet Classes
Description: The intervention is ballet classes three times a week, 1 hour and 30 min. The ballet classes consists in barre work and center work with specific ballet exercises.
Study: NCT03594266

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapy A spinal cord stimulation parameter set using BIO-RNA system and associated components
Description: Therapy A stimulation patterns
Study: NCT02401464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-536 Tablet
Description: TAK-536 10 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-536 Tablet
Description: TAK-536 10 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-536 Dry Syrup Formulation
Description: TAK-536 dry syrup formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-536 Dry Syrup Formulation
Description: TAK-536 dry syrup formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-536 Ganule Formulation
Description: TAK-536 granule formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-536 Ganule Formulation
Description: TAK-536 granule formulation
Study: NCT03145766

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRVg 2
Description: Modified formulation 1 (Low) of Purified Vero Rabies Vaccine Serum Free

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRVg 1
Description: Initial formulation of Purified Vero Rabies Vaccine Serum Free

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Imovax Rabies
Description: Purified inactivated rabies vaccine prepared on human diploid cell cultures

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRVg 2
Description: Modified formulation 2 (Medium) of Purified Vero Rabies Vaccine Serum Free

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRVg 2
Description: Modified formulation 3 (High) of Purified Vero Rabies Vaccine Serum Free

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Rabies Immunoglobulins (HRIG)
Description: Commercialized formulation of HRIG

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Rabies Immunoglobulins (HRIG)
Description: Commercialized formulation of HRIG

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Rabies Immunoglobulins (HRIG)
Description: Commercialized formulation of HRIG

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Rabies Immunoglobulins (HRIG)
Description: Commercialized formulation of HRIG

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human Rabies Immunoglobulins (HRIG)
Description: Commercialized formulation of HRIG
Study: NCT03850080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Conditioned Serum
Description: Fifteen patients with clinical and radiological signs of OA of the knee were recruited for this study. 50mL of whole blood were taken using a special syringe containing CrSO4-coated grade glass beads in order to promote IL-1ra synthesis and aggregation.The incubation period lasted 7 hours after which, the blood-filled syringes were centrifuged and the serum supernatant was filtered and aliquoted into four 3mL portions. The aliquots were stored at -20oC until their use was necessary.~Patients received 1 intra-articular injection for 4 consecutive weeks at the site of OA.
Study: NCT00745706

Intervention type: DEVICE
Group type: OTHER
Intervention: Implantable Loop Recorder (ILR)
Description: Insertion of ILR 3 months prior to clinical ablation procedure to collect data on actual Atrial Fibrillation episodes and correlation with patient symptoms through patient diary entry. Then patient undergoes their previously indicated clinical ablation procedure and is then followed up with ILR insitu for 30 months post-ablation for the same as mentioned above.
Study: NCT03818789

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness and acceptance training
Description: A breathing mediation, body scan, talking about acceptance, and presence activity are used. All are low-impact and expected to cause no distress

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Study skills video
Description: A YouTube video describing study skills and suggested habits is used as a control condition.
Study: NCT03161457

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JHL1101
Description: 1000 mg containing 10 mg/mL rituximab to be diluted to a concentration of 1 to 4 mg/mL in 0.9% normal saline or 5% D-glucose for administration

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MabThera
Description: 1000 mg containing 10 mg/mL rituximab to be diluted to a concentration of 1 to 4 mg/mL in 0.9% normal saline or 5% D-glucose for administration
Study: NCT03381404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] MT-8554
Description: 14-C MT-8554
Study: NCT01724645

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Korean traditional diets
Description: The consumption of Korean traditional diets reflecting the characteristics of Korean traditional diets without the limitation of calories has an effect on control of cardiovascular risk factor, so this study instructed all subjects of the intervention group to consume about 2,100kcal of served meals freely.~The Korean Traditional diets, which encourages the intake of cooked rice, vegetables,soup,Kimchi and soy fermented foods.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Told to  eat as usal diets.
Study: NCT03158363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LPS, 36 hour immobilization and fast
Description: LPS endotoxin is administered on study day 1 and immobilization and fast continue throughout study day 1 and 2.
Study: NCT00581620

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pneumococcus conjugate vaccine
Description: Infants from 1 to 6 months: 3 doses at 2; 4; 6 m and booster from 12 to 15 months.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pneumococcus conjugate vaccine
Description: Infants from 1 to 6 months: 3 doses at 2; 4; 6 m and booster from 12 to 15 months.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pneumococcus conjugate vaccine
Description: Infants from 1 to 6 months: 3 doses at 2; 4; 6 m and booster from 12 to 15 months.
Study: NCT03199157

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl transdermal patch
Description: Patients received fentanyl 12 mcg transdermal patch group 8 hours preoperatively and until 24 hours after the surgery
Study: NCT04389879

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bonding of either CAD/CAM or conventional multistranded stainless steel fixed retainer
Description: Investigate and compare the clinical effectiveness of two types of fixed retainers; CAD/CAM vs. multistranded wire.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bonding of either CAD/CAM or conventional multistranded stainless steel fixed retainer
Description: Investigate and compare the clinical effectiveness of two types of fixed retainers; CAD/CAM vs. multistranded wire.
Study: NCT02264951

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tributyrin
Description: a triglyceride containing three C4-acids

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: C8-diet oil
Description: a triglyceride containing 2 C8-fatty acids and one oleic acid at sn-2 position

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Olive oil
Description: a triglyceride containing mostly three oleic acids

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carrot
Description: mainly water and glucose

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carrot
Description: mainly water and glucose

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carrot
Description: mainly water and glucose

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carrot
Description: mainly water and glucose
Study: NCT01543100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood and bone marrow samples
Description: Specific tests of the study will be realized from :~* Blood samples: 2 EDTA tubes and 1 tube without anticoagulant per included patient.~* Bone marrow: 3 ml collected during of myelogram punction made for the diagnosis.~In all cases, no additional sampling will be performed.
Study: NCT01127009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study: NCT02222766

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents and Tots Together Program
Description: Group-based parenting program, 9 sessions offered weekly

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Minimal attention control- 9 weekly mailed information on general child development
Study: NCT05719948

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flouroscopic guidance cervical medial branch radiofrequency ablation
Description: Electromagnetic wave deposition near nerve tissue for pain management

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flouroscopic guidance cervical medial branch radiofrequency ablation
Description: Electromagnetic wave deposition near nerve tissue for pain management
Study: NCT03594266

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapy B spinal cord stimulation parameter set using BIO-RNA system and associated components
Description: Therapy B stimulation patterns
Study: NCT02284802

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Confocal endomicroscopy
Description: Confocal endomicroscopy examination during endoscopy
Study: NCT00719238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition plus education
Description: Nutritional instruction in small groups plus education

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education only
Description: Educational video and pamphlets